Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally ava...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-04-01
Edice:	Gynecologic Oncology Reports
Témata:	Abemaciclib Aromatase inhibition CDK4/6 inhibition PI3K inhibition LY3023414 Endometrial cancer
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352578924000274
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!